Abstract
ObjectivesJanus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have